• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

SmartCells

edit

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company’s polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

Recent Milestones

edit

• 
  SmartCells was acquired by Merck & Co. for $500M. (12/3/10)
  Posted 12/7/10 at 7:47pm via dowjones.com
• 
  SmartCells — SmartCells Inc., a Beverly diabetes drug developer, is to be acquired by Merck & Co. Inc. for a total of about $500 million (12/2/10)
  Posted 12/2/10 at 8:25am via masshightech.com
• 
  SmartCells received $4.1M in Series D funding. (6/17/10)
  Posted 7/21/10 at 8:40pm via smartinsulin.com
• 
  SmartCells added Todd C. Zion as President, Co-founder & CEO.
  Posted 7/21/10 at 8:40pm
• 
  SmartCells added Alan Watson as Vice President of Business Development.
  Posted 7/21/10 at 8:40pm

Videos

Screenshots

edit

Sources

1. Angel Backing Lifted SmartCells To $500M Merck Acquisition (fis.dowjones.com) [edit]
2. SmartCells Completes Series D Preferred Stock Financing (smartinsulin.com) [edit]
Merck acquires diabetes drug firm SmartCells (masshightech.com) [edit]